SCHEMBL26879283

SCHEMBL26879283

CC[C@H]1OC[C@@H](N2CCOC2=O)[C@@H](OCc2ccccc2)[C@H]1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAAA Q02083 4/20 0.38
▸ FAAH O00519 2/20 0.38
▸ GRM2 Q14416 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ CTSV O60911 1/20 0.35
▸ CTSL P07711 1/20 0.35
▸ CTSB P07858 1/20 0.35
▸ CTSS P25774 1/20 0.35
▸ CTSK P43235 1/20 0.35
▸ CTSC P53634 1/20 0.35
▸ CTSF Q9UBX1 1/20 0.35
▸ PDE4B Q07343 1/20 0.34
▸ BCHE P06276 1/20 0.33
▸ PDPK1 O15530 1/20 0.33
▸ MTOR P42345 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ SLC6A2 P23975 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26879340 0.85 MAPT (0.36) GRM2MAPTCYP2C19CTSVCTSL
SCHEMBL24256523 0.82 HTR1A (0.39) NAAAFAAHCTSVCTSLCTSB
SCHEMBL26879276 0.81 KMT2A (0.36) SLC6A2MAPK1
SCHEMBL26879300 0.81 PSEN1 (0.39) MAPTCYP2C19CTSVCTSLCTSB
SCHEMBL26879302 0.81 MAPT (0.35) GRM2MAPTCYP2C19CTSVCTSL
SCHEMBL26879331 0.81 BCHE (0.37) GRM2MAPTCYP2C19CTSVCTSL
SCHEMBL26879321 0.80 SLC6A2 (0.37) MAPTCYP2C19CTSLCTSBCTSK
SCHEMBL26879312 0.80 GRM5 (0.35) MAPTCYP2C19CTSVCTSLCTSB
SCHEMBL26879316 0.80 CASP1 (0.35) MAPTPDE4BBCHE
SCHEMBL26879446 0.78 TACR1 (0.36) MAPTBCHESLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 — — US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A NAAA 2212/4885FAAH 2351/4885GRM2 1864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback